Related Experiment Videos
Fluconazole
P B Agrawal1, A Narang, P Kumar
1Department of Pediatrics, Post Graduate Institute for Medical Education and Research, Chandigarh.
Abstract:
Incidence of systemic candidiasis is increasing with improvement in the survival of high risk neonates who undergo multiple interventions. Therapies available to treat systemic fungal infection are few and have several drawbacks. Fluconazole, a new triazole derivative may be a useful anti-fungal agent in view of its excellent oral absorption, easy administration, low plasma protein affinity, long half-life, high concentrations in urine and CSF, minimal adverse reactions, wide spectrum of anti-fungal activity and high specificity for fungal cytochrome P450 system. Its utility in neonates and children with candidiasis has already been documented by few case reports and studies.
Insights
Systemic candidiasis is rising in high-risk neonates. Fluconazole shows promise as a safe and effective antifungal treatment due to its favorable pharmacokinetic profile and minimal side effects.
Area of Science:
- Medical Mycology
- Neonatal Medicine
- Pharmacology
Background:
- Systemic candidiasis incidence is increasing in neonates due to improved survival rates and invasive interventions.
- Current antifungal therapies possess limitations and drawbacks, necessitating alternative treatments.
Purpose of the Study:
- To evaluate the potential utility of fluconazole as an antifungal agent in neonatal candidiasis.
Main Methods:
- Literature review of fluconazole's properties and existing case reports/studies in neonates and children.
- Analysis of fluconazole's pharmacokinetic profile, including absorption, distribution, metabolism, and excretion.
- Assessment of fluconazole's safety and efficacy based on reported adverse reactions and clinical outcomes.
Main Results:
- Fluconazole exhibits excellent oral absorption, a long half-life, and high concentrations in urine and cerebrospinal fluid (CSF).
- It demonstrates a wide spectrum of antifungal activity and high specificity for the fungal cytochrome P450 system.
- Minimal adverse reactions were observed, suggesting a favorable safety profile.
Conclusions:
- Fluconazole presents a promising therapeutic option for neonatal candidiasis.
- Its favorable pharmacokinetic properties and safety profile support its use in this vulnerable population.